Suncoast Equity Management Has $1.05 Million Stake in STERIS plc $STE

Suncoast Equity Management raised its position in STERIS plc (NYSE:STE) by 5.0% during the second quarter, according to its most recent filing with the SEC. The firm owned 4,362 shares of the medical equipment provider’s stock after purchasing an additional 207 shares during the period. Suncoast Equity Management’s holdings in STERIS were worth $1,048,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of STE. Geneos Wealth Management Inc. lifted its position in shares of STERIS by 416.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 104 shares during the period. Zions Bancorporation National Association UT acquired a new position in shares of STERIS in the 1st quarter worth approximately $37,000. Costello Asset Management INC acquired a new position in shares of STERIS in the 1st quarter worth approximately $45,000. Atticus Wealth Management LLC acquired a new position in shares of STERIS in the 2nd quarter worth approximately $68,000. Finally, SVB Wealth LLC acquired a new position in shares of STERIS in the 1st quarter worth approximately $69,000. Institutional investors and hedge funds own 94.69% of the company’s stock.

Insider Transactions at STERIS

In other STERIS news, CEO Daniel A. Carestio sold 159 shares of the firm’s stock in a transaction on Monday, October 6th. The shares were sold at an average price of $241.82, for a total value of $38,449.38. Following the transaction, the chief executive officer directly owned 51,096 shares of the company’s stock, valued at approximately $12,356,034.72. This trade represents a 0.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Karen L. Burton sold 7,900 shares of the firm’s stock in a transaction on Monday, August 11th. The shares were sold at an average price of $241.73, for a total transaction of $1,909,667.00. Following the completion of the transaction, the chief accounting officer directly owned 5,994 shares in the company, valued at $1,448,929.62. This trade represents a 56.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 18,868 shares of company stock valued at $4,585,389. Corporate insiders own 1.07% of the company’s stock.

Wall Street Analyst Weigh In

STE has been the topic of a number of recent analyst reports. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research report on Tuesday, October 14th. Morgan Stanley lifted their price objective on shares of STERIS from $276.00 to $295.00 and gave the company an “overweight” rating in a research note on Friday, August 8th. KeyCorp boosted their target price on shares of STERIS from $277.00 to $288.00 and gave the company an “overweight” rating in a research report on Tuesday, July 22nd. Finally, Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 14th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $273.50.

STERIS Stock Up 0.6%

STERIS stock opened at $243.24 on Thursday. The company has a quick ratio of 1.53, a current ratio of 2.22 and a debt-to-equity ratio of 0.27. STERIS plc has a 12-month low of $200.98 and a 12-month high of $253.00. The firm’s fifty day moving average is $243.30 and its 200 day moving average is $238.43. The company has a market capitalization of $23.96 billion, a PE ratio of 37.25 and a beta of 1.02.

STERIS (NYSE:STE) last announced its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.38 by $0.09. STERIS had a net margin of 11.61% and a return on equity of 14.17%. The business had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.43 billion. During the same quarter in the previous year, the business posted $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. As a group, sell-side analysts predict that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Shareholders of record on Tuesday, November 18th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, November 18th. STERIS’s dividend payout ratio (DPR) is 38.59%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.